Enliven Therapeutics is focused on developing innovative precision oncology therapies, particularly small molecule kinase inhibitors, to improve the treatment landscape for cancer patients. Their lead product candidates, ELVN-001 and ELVN-002, are designed to address significant challenges in cancer treatment, such as drug resistance, tolerability, and the management of brain metastases. ELVN-001 specifically targets the BCR-ABL gene fusion associated with chronic myeloid leukemia (CML), offering a highly selective mechanism of action that aims to overcome common resistance mutations and improve patient convenience. This candidate is currently undergoing evaluation in a Phase 1 clinical trial, with promising proof of concept data already reported.

ELVN-002, on the other hand, is an irreversible HER2 inhibitor that penetrates the central nervous system and targets both wild-type HER2 and various mutations linked to aggressive solid tumors, including breast and lung cancers. This compound is designed to minimize toxicity by sparing wild-type EGFR, thereby potentially enhancing the therapeutic index compared to existing treatments. ELVN-002 is also being assessed in a Phase 1 clinical trial, with a focus on its efficacy in patients with HER2-altered cancers, particularly those who have progressed on or are intolerant to current therapies. Enliven Therapeutics is committed to advancing these programs while exploring additional research opportunities to further enhance their oncology pipeline.

United States

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

Cancer

Enliven Therapeutics

Blood cancer

Chronic myelomonocytic leukemia

<p class="font_8">ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML</p>

ELVN-001

Metastatic breast cancer

Metastatic colorectal cancer

<p class="font_8">ELVN-002 is a potent, highly selective, central nervous system penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.</p>

Enliven Therapeutics

Company Details